Regeneron Pharmaceuticals

Open: 792.4 Close: 775.18 Change: -17.22

You're losing the opportunity of using an AI to get informed about Regeneron Pharmaceuticals Company Inc Stock.

How much time have you spent trying to decide whether investing in Regeneron Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The company's products include EYLEA injection to treat neovascular age-related macular degeneration.

Today's Summary

Regeneron Pharmaceuticals Inc. stock falls friday, underperforms market - marketwatch.com.com. The score for REGN is 52, which is 4%.

Today's News

Regeneron Pharmaceuticals Inc. stock falls friday, underperforms market - marketwatch.com. Regeneron pharmaceuticals inc. stock fell friday,. underperforming market. Regeneron Pharmaceuticals stock price is $775.81. The current share price is 775.81. The score for REGN is 52, which is 4%. Regeneron Pharmaceuticals, Inc. (regn) stock price, quote & news - stock analysis. Regeneron stock dropped from $797.04 to $792.76 as of 3:14 PM on Thursday, Oct 26, a drop of -$4.28, or -0.54% from the previous closing of $797. The biotech company scored a 93 in the Healthcare sector. Regeneron Pharmaceuticals stock is 116.32% away from the 52-week low. The high in the last 52 weeks of Regeneron pharmaceuticals stock was 853.97. The current price is 645.11 Bid 100.00 Ask 100.24. Regeneron Pharmaceuticals stock opened at $795.54 on Friday. Canaccord Genuity Group raised shares of Regeneron pharmaceuticals from a “hold” rating to a ‘buy’ rating. Virtu Financial purchased 9,431 shares of the company.

Stock Profile

"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York."

Keywords

The game is changing. There is a new strategy to evaluate Regeneron Pharmaceuticals fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, stock, Pharmaceuticals, price, pharmaceutical, share, Inc, and the most common words in the summary are: regeneron, pharmaceutical, stock, market, job, news, price, . One of the sentences in the summary was: The score for REGN is 52, which is 4%.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #regeneron #pharmaceutical #stock #market #job #news #price.